The efficacy of cefdinir in acute bacterial rhinosinusitis

Abstract

Acute bacterial rhinosinusitis is a common infection resulting in substantial morbidity. Cefdinir, an oral cephalosporin, has extended-spectrum, bactericidal activity against common acute bacterial rhinosinusitis pathogens, including Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Cefdinir shows rapid oral absorption and good respiratory tissue penetration, and may be administered once daily. In randomised clinical trials, cefdinir showed efficacy similar to that of other recommended regimens in the treatment of acute bacterial rhinosinusitis, namely amoxicillin/clavulanate and levofloxacin. Cefdinir is well tolerated and has shown a low propensity to suppress the normal commensal flora. Cefdinir oral suspension is rated highly by children in terms of its taste and smell. As the only once-daily beta-lactam currently recommended by acute bacterial rhinosinusitis guidelines (for first-line use in patients with mild acute bacterial rhinosinusitis and no recent antibacterial use), cefdinir offers a convenient and attractive treatment option.

A comparative study between amoxicillin + clavulanic acid and levofloxacin in the management of acute maxillary sinusitis at RIMS, Ranchi

“…[3][4][5] The treatment of choice for mild cases of sinusitis are amoxicillinclavulanate or cefadroxil, while amongst moderate or mild patients who have been previously treated with antibiotics, levofloxacin or moxifloxacin are the treatment of choice, whilst in the severe forms, third generation cephalosporins, like cefotaxime or ceftriaxone or cefixime are used. [6][7][8] Various clinical studies have shown the success rate of amoxicillin/clavulanate to be 96.7%. 9 The success rate of levofloxacin as a treatment modality for rhinosinusitis was 88.4% in one study.…”

Comparative Bioavailability of Two Cefdinir Suspension Formulations in Middle Eastern Healthy Volunteers after Single Oral Administration

“…In fact, large doses of cefdinir yield an overall successful clinical response at the end of the treatment in children affected by acute otitis media and at risk for persistent recurrent infection [4]. Furthermore, the efficacy of this drug was recently evaluated in acute bacterial rhinosinusitis by Hardley [5], who found that cefdinir offered a convenient and attractive treatment option since it is the only once daily beta-lactam currently recommended for this infection (for first-line use in patients with mild acute bacterial rhinosinusitis and no recent antibacterial use). Also the suspension dosage form of this drug is highly rated by children in terms of taste and smell; children 4 to 8 years of age preferred the taste and smell of cefdinir oral suspension to those of amoxicillin/clavulanate potassium, cefprozil and azithromycin [6].…”